Leila Alizadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leila Alizadeh has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Masoud Nouri-Vaskeh
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
6 shared publications - Aida Malek Mahdavi
Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
3 shared publications - Sina Hamzehzadeh
Student Research Committee Tabriz University of Medical Sciences Tabriz Iran
3 shared publications Hossein Afshan
Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publicationsMohammad Zarei
Departrment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA; Center for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia, Philadelphia, USA
2 shared publications- Zeinab Nikniaz
Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications
Latest Publications
- Open Access
- 25 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-7
Association of serum trace elements with non-invasive fibrosis scores in metabolic dysfunction-associated steatotic liver disease
Liver biopsy is not a routine screening tool for detecting fibrosis progression in metabolic dysfunction-associated steatotic liver disease (MASLD). Noninvasive methods based on serum biomarkers are used instead. This study evaluated the relationship between serum zinc (Zn), copper (Cu), and ceruloplasmin levels and non-invasive criteria for hepatic fibrosis, including Fibrosis-4 (FIB-4), Nonalcoholic Fatty Liver Disease fibrosis score (NFS), and BARD, in patients with MASLD. In this prospective cross-sectional study, a total of 134 MASLD patients referred to the gastroenterology clinic of Imam Reza Hospital and Sheikh AlRaees Clinic, Tabriz, in 2022 were included. Serum levels of Zn, Cu, ceruloplasmin, albumin, complete blood count (CBC), fasting blood sugar (FBS), Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were checked. Also, non-invasive measures of FIB-4, NFS, and BARD were measured. Finally, the relationship between the levels of Zn, Cu, and ceruloplasmin with each of the FIB-4, NFS, and BARD criteria was investigated. Zn serum levels were significantly lower in FIB-4 3 than in FIB-4 1 and 2 (P-value < 0.01); however, no significant relationship was found between serum Cu and ceruloplasmin variables with FIB-4 (P > 0.05). Zn serum levels were also significantly higher in NFS fibrosis score 1 (P-value < 0.01). There was no significant relationship between serum Cu and ceruloplasmin variables with NFS fibrosis score in the studied patients (P > 0.05). No significant relationship was observed between serum Zn, Cu, and ceruloplasmin with the BARD fibrosis score in the studied patients (P > 0.05). It seems that among the levels of Zn, Cu, and ceruloplasmin serum with non-invasive measures of liver fibrosis, including FIB-4, NFS, and BARD in MASLD patients, there is only a significant relationship between serum Zn level and FIB-4 and NFS criteria. And therefore, Zn may serve as a potential biomarker.
- 25 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-7
Open AccessAssociation of serum trace elements with non-invasive fibrosis scores in metabolic dysfunction-associated steatotic liver disease
Liver biopsy is not a routine screening tool for detecting fibrosis progression in metabolic dysfunction-associated steatotic liver disease (MASLD). Noninvasive methods based on serum biomarkers are used instead. This study evaluated the relationship between serum zinc (Zn), copper (Cu), and ceruloplasmin levels and non-invasive criteria for hepatic fibrosis, including Fibrosis-4 (FIB-4), Nonalcoholic Fatty Liver Disease fibrosis score (NFS), and BARD, in patients with MASLD. In this prospective cross-sectional study, a total of 134 MASLD patients referred to the gastroenterology clinic of Imam Reza Hospital and Sheikh AlRaees Clinic, Tabriz, in 2022 were included. Serum levels of Zn, Cu, ceruloplasmin, albumin, complete blood count (CBC), fasting blood sugar (FBS), Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were checked. Also, non-invasive measures of FIB-4, NFS, and BARD were measured. Finally, the relationship between the levels of Zn, Cu, and ceruloplasmin with each of the FIB-4, NFS, and BARD criteria was investigated. Zn serum levels were significantly lower in FIB-4 3 than in FIB-4 1 and 2 (P-value < 0.01); however, no significant relationship was found between serum Cu and ceruloplasmin variables with FIB-4 (P > 0.05). Zn serum levels were also significantly higher in NFS fibrosis score 1 (P-value < 0.01). There was no significant relationship between serum Cu and ceruloplasmin variables with NFS fibrosis score in the studied patients (P > 0.05). No significant relationship was observed between serum Zn, Cu, and ceruloplasmin with the BARD fibrosis score in the studied patients (P > 0.05). It seems that among the levels of Zn, Cu, and ceruloplasmin serum with non-invasive measures of liver fibrosis, including FIB-4, NFS, and BARD in MASLD patients, there is only a significant relationship between serum Zn level and FIB-4 and NFS criteria. And therefore, Zn may serve as a potential biomarker.
- 3 September 2025
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 69, 809-820
Omega-3 fatty acid supplementation in solid organ transplant recipients: A systematic review and meta-analysis of randomized controlled trials
- 3 September 2025
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 69, 809-820
Omega-3 fatty acid supplementation in solid organ transplant recipients: A systematic review and meta-analysis of randomized controlled trials
- Open Access
- 15 April 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-6
Association of ultrasound signs of sarcopenia with serum ferritin levels and hepatic indices like NFS and FIB-4 in NAFLD patients
Non-alcoholic fatty liver disease is one of the most common chronic diseases all around the world, which significantly correlates with metabolic disorders and inflammatory cycles. Sarcopenia is a decrease in the mass of skeletal muscles interacting with factors such as inflammatory processes and chronic diseases. It can also lead to the aggravation of chronic diseases. The study population was randomly selected and entered into the research based on exclusion and inclusion criteria. Non-alcoholic fatty liver disease was confirmed in all members of the study population by ultrasound. Patients’ serum ferritin level was assessed, and their NFS and Fib 4 scores were calculated. Sarcopenia was diagnosed by measuring the thickness of the rectus femoris by ultrasonography. The correlation between these variables was evaluated and analyzed by statistical software. According to statistical analysis, there is a significant association between the serum ferritin level and sarcopenia (P-value < 0.001). Besides, there is a significant association between NFS, Fib4, and sarcopenia (P-value = 0.024, 0.000). This research’s results reflect the correlation between serum ferritin and sarcopenia; however, it cannot conclude a cause-and-effect relationship between these variables.
- 15 April 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-6
Open AccessAssociation of ultrasound signs of sarcopenia with serum ferritin levels and hepatic indices like NFS and FIB-4 in NAFLD patients
Non-alcoholic fatty liver disease is one of the most common chronic diseases all around the world, which significantly correlates with metabolic disorders and inflammatory cycles. Sarcopenia is a decrease in the mass of skeletal muscles interacting with factors such as inflammatory processes and chronic diseases. It can also lead to the aggravation of chronic diseases. The study population was randomly selected and entered into the research based on exclusion and inclusion criteria. Non-alcoholic fatty liver disease was confirmed in all members of the study population by ultrasound. Patients’ serum ferritin level was assessed, and their NFS and Fib 4 scores were calculated. Sarcopenia was diagnosed by measuring the thickness of the rectus femoris by ultrasonography. The correlation between these variables was evaluated and analyzed by statistical software. According to statistical analysis, there is a significant association between the serum ferritin level and sarcopenia (P-value < 0.001). Besides, there is a significant association between NFS, Fib4, and sarcopenia (P-value = 0.024, 0.000). This research’s results reflect the correlation between serum ferritin and sarcopenia; however, it cannot conclude a cause-and-effect relationship between these variables.
- Open Access
- 21 October 2024
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
Investigation of the diagnostic value of neutrophil-to-lymphocyte ratio for evaluating the severity of pancreatitis in patients with acute pancreatitis
Background. Acute pancreatitis (AP) is considered a gastrointestinal disorder that may lead to a systemic inflammatory response and requires urgent hospitalization. Currently, the bedside index of severity in acute pancreatitis (BISAP) scoring system is used to estimate the severity of the disease. This study sought to investigate the significant relationship between the infectious inflammatory components of the neutrophil-to-lymphocyte ratio (NLR), which can only be obtained by a simple blood test. Then, this ratio was compared with the BISAP scoring system. Methods. This cohort study was conducted at Imam Reza Hospital of Tabriz University of Medical Sciences in 2017‒2018. A total of 98 hospitalized patients with our desired criteria were included in the study. A complete blood count differential was obtained, and the BISAP score was calculated and analyzed, along with demographic data. Results. The NLR and the age of patients had a significant relationship with the BISAP variable (P < 0.05). For one unit (year) increase in patients’ age, the chance of being placed in the higher categories of the BISAP score increased by 1.14 and 1.09 times, respectively. Gender, smoking, and underlying diseases had no significant relationship with the BISAP score (P > 0.05). Conclusion. The initial values of the NLR can be used to determine the prognosis and severity of the disease in patients with acute pancreatitis in a quick, easy, and accessible way. Practical Implications. Simple ratios such as NLR can be utilized to perform immediate measurements for the management of acute pancreatitis.
- 21 October 2024
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
Open AccessInvestigation of the diagnostic value of neutrophil-to-lymphocyte ratio for evaluating the severity of pancreatitis in patients with acute pancreatitis
Background. Acute pancreatitis (AP) is considered a gastrointestinal disorder that may lead to a systemic inflammatory response and requires urgent hospitalization. Currently, the bedside index of severity in acute pancreatitis (BISAP) scoring system is used to estimate the severity of the disease. This study sought to investigate the significant relationship between the infectious inflammatory components of the neutrophil-to-lymphocyte ratio (NLR), which can only be obtained by a simple blood test. Then, this ratio was compared with the BISAP scoring system. Methods. This cohort study was conducted at Imam Reza Hospital of Tabriz University of Medical Sciences in 2017‒2018. A total of 98 hospitalized patients with our desired criteria were included in the study. A complete blood count differential was obtained, and the BISAP score was calculated and analyzed, along with demographic data. Results. The NLR and the age of patients had a significant relationship with the BISAP variable (P < 0.05). For one unit (year) increase in patients’ age, the chance of being placed in the higher categories of the BISAP score increased by 1.14 and 1.09 times, respectively. Gender, smoking, and underlying diseases had no significant relationship with the BISAP score (P > 0.05). Conclusion. The initial values of the NLR can be used to determine the prognosis and severity of the disease in patients with acute pancreatitis in a quick, easy, and accessible way. Practical Implications. Simple ratios such as NLR can be utilized to perform immediate measurements for the management of acute pancreatitis.
- Open Access
- 11 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-8
The impact of piperine on the metabolic conditions of patients with NAFLD and early cirrhosis: a randomized double-blind controlled trial
Non-alcoholic fatty liver disease (NAFLD) is a metabolic dysfunction of the liver defined as an abnormal accumulation of fat within the liver without secondary triggers like alcohol consumption or viral hepatitis. Piperine, the bio-active ingredient of black pepper, can exert a significant function in treatment of individuals with NAFLDand early cirrhosis. We investigated the impact of piperine consumption with a duration of 12 weeks on patients with NAFLD and early cirrhosis compared toplacebo consumption. In a double-blind study, patients with NAFLD and early stage of cirrhosis were haphazardly distributed into case and control groups. They were prescribed a placebo and 5 mg of piperine for 12 weeks, respectively. The demographic and laboratory parameters of individuals were assessed as the baseline and after the duration of piperine intake. Piperine with a daily dosage of 5 mg could significantly decrease hepatic enzymes and glucose, and alleviate dyslipidemia in the case arm rather than the control arm. Moreover, HOMA levels and insulin resistance were reduced in case participants compared to the control counterparts. In the absence of approved medicinal intervention for patients with NAFLD, and regarding the favorable impact of piperine on NAFLD more studies on this subject are warranted.
- 11 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-8
Open AccessThe impact of piperine on the metabolic conditions of patients with NAFLD and early cirrhosis: a randomized double-blind controlled trial
Non-alcoholic fatty liver disease (NAFLD) is a metabolic dysfunction of the liver defined as an abnormal accumulation of fat within the liver without secondary triggers like alcohol consumption or viral hepatitis. Piperine, the bio-active ingredient of black pepper, can exert a significant function in treatment of individuals with NAFLDand early cirrhosis. We investigated the impact of piperine consumption with a duration of 12 weeks on patients with NAFLD and early cirrhosis compared toplacebo consumption. In a double-blind study, patients with NAFLD and early stage of cirrhosis were haphazardly distributed into case and control groups. They were prescribed a placebo and 5 mg of piperine for 12 weeks, respectively. The demographic and laboratory parameters of individuals were assessed as the baseline and after the duration of piperine intake. Piperine with a daily dosage of 5 mg could significantly decrease hepatic enzymes and glucose, and alleviate dyslipidemia in the case arm rather than the control arm. Moreover, HOMA levels and insulin resistance were reduced in case participants compared to the control counterparts. In the absence of approved medicinal intervention for patients with NAFLD, and regarding the favorable impact of piperine on NAFLD more studies on this subject are warranted.
- 4 July 2022
- Published by Maad Rayan Publishing Company in Journal of Research in Clinical Medicine
- Vol. 10 (1) , 9
Clinical course and outcome of COVID-19 in patients with autoimmune inflammatory diseases under treatment with TNF inhibitors
Clinical course and outcome of COVID-19 in patients with autoimmune inflammatory diseases under treatment with TNF inhibitors
- 4 July 2022
- Published by Maad Rayan Publishing Company in Journal of Research in Clinical Medicine
- Vol. 10 (1) , 9
Clinical course and outcome of COVID-19 in patients with autoimmune inflammatory diseases under treatment with TNF inhibitors
Clinical course and outcome of COVID-19 in patients with autoimmune inflammatory diseases under treatment with TNF inhibitors
- 12 October 2020
- Published by Taylor & Francis in Archives of Physiology and Biochemistry
- Vol. 129 (2) , 373-378
Circulating glucagon-like peptide-1 level in patients with liver cirrhosis
Glucagon-like peptide-1 (GLP-1), a gut-derived incretin hormone, plays a pivotal role in glucose-induced insulin secretion. Currently, the role of incretin hormones in the pathogenesis of cirrhosis...
- 12 October 2020
- Published by Taylor & Francis in Archives of Physiology and Biochemistry
- Vol. 129 (2) , 373-378
Circulating glucagon-like peptide-1 level in patients with liver cirrhosis
Glucagon-like peptide-1 (GLP-1), a gut-derived incretin hormone, plays a pivotal role in glucose-induced insulin secretion. Currently, the role of incretin hormones in the pathogenesis of cirrhosis...
- 1 April 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (10) , 1731-1732
Fecal transmission in COVID‐19: A potential shedding route
- 1 April 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (10) , 1731-1732
Fecal transmission in COVID‐19: A potential shedding route
- 1 March 2020
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 49, 102351
Curcumin ameliorates health-related quality of life in patients with liver cirrhosis: A randomized, double-blind placebo-controlled trial
- 1 March 2020
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 49, 102351
Curcumin ameliorates health-related quality of life in patients with liver cirrhosis: A randomized, double-blind placebo-controlled trial
- 3 February 2020
- Published by Wiley in Phytotherapy Research
- Vol. 34 (6) , 1446-1454
Effect of curcumin supplementation on disease severity in patients with liver cirrhosis: A randomized controlled trial
Recent reports indicated that curcumin had beneficial effects in animal models of liver injury and cirrhosis. Current study aimed to investigate the effects of curcumin supplementation in patients with liver cirrhosis. In this randomized double‐blind placebo‐controlled trial, 70 patients with liver cirrhosis aged 20–70 years were randomly divided into two groups to receive 1,000 mg/day curcumin (n = 35) or placebo (n = 35) for 3 months. Model for end‐stage liver disease (MELD) (i), MELD, MELD‐Na, and Child–Pugh scores were used to assess the severity of cirrhosis. Sixty patients (29 in the curcumin group and 31 in the placebo group) completed the study. MELD(i) (15.55 ± 3.78 to 12.41 ± 3.07), MELD (15.31 ± 3.07 to 12.03 ± 2.79), MELD‐Na (15.97 ± 4.02 to 13.55 ± 3.51), and Child–Pugh (7.17 ± 1.54 to 6.72 ± 1.31) scores decreased significantly in the curcumin group after 3‐month intervention (p < .001, p < .001, p = .001, and p = .051, respectively), whereas they increased significantly in the placebo group (p < .001, p < .001, p < .001, p = .001, respectively). Significant differences were only observed between the two groups in MELD(i), MELD, MELD‐Na, and Child–Pugh scores after 3‐month intervention (p < .001 for all of them). In this pilot study, beneficial effects of curcumin supplementation were observed in decreasing disease activity scores and severity of cirrhosis in patients with cirrhosis.
- 3 February 2020
- Published by Wiley in Phytotherapy Research
- Vol. 34 (6) , 1446-1454
Effect of curcumin supplementation on disease severity in patients with liver cirrhosis: A randomized controlled trial
Recent reports indicated that curcumin had beneficial effects in animal models of liver injury and cirrhosis. Current study aimed to investigate the effects of curcumin supplementation in patients with liver cirrhosis. In this randomized double‐blind placebo‐controlled trial, 70 patients with liver cirrhosis aged 20–70 years were randomly divided into two groups to receive 1,000 mg/day curcumin (n = 35) or placebo (n = 35) for 3 months. Model for end‐stage liver disease (MELD) (i), MELD, MELD‐Na, and Child–Pugh scores were used to assess the severity of cirrhosis. Sixty patients (29 in the curcumin group and 31 in the placebo group) completed the study. MELD(i) (15.55 ± 3.78 to 12.41 ± 3.07), MELD (15.31 ± 3.07 to 12.03 ± 2.79), MELD‐Na (15.97 ± 4.02 to 13.55 ± 3.51), and Child–Pugh (7.17 ± 1.54 to 6.72 ± 1.31) scores decreased significantly in the curcumin group after 3‐month intervention (p < .001, p < .001, p = .001, and p = .051, respectively), whereas they increased significantly in the placebo group (p < .001, p < .001, p < .001, p = .001, respectively). Significant differences were only observed between the two groups in MELD(i), MELD, MELD‐Na, and Child–Pugh scores after 3‐month intervention (p < .001 for all of them). In this pilot study, beneficial effects of curcumin supplementation were observed in decreasing disease activity scores and severity of cirrhosis in patients with cirrhosis.